Sugammadex

Summary

Sugammadex (CHEMBL2111107) is an approved oligosaccharide (ATC V03AB35); indicated across 9 conditions including burn and morbid obesity.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Oligosaccharide
• ATC class: V03AB35
• Indications: 9 conditions
• Clinical trials: 208
• Chemistry: 2002.2 Da · C72H112O48S8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2111107
Name	Sugammadex
Type	Oligosaccharide
Max phase	4
FDA approved	no
PubChem CID	70693550
ATC	V03AB35
Molecular formula	C72H112O48S8
Molecular weight	2002.2
InChIKey	WHRODDIHRRDWEW-ZWYCLXBASA-N

SMILES: C(CSC[C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H](C([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)CSCCC(=O)O)O)O)C(=O)O

IUPAC name: 3-[[(1S,3S,5S,6S,8S,10S,11S,13S,15S,16S,18S,20S,21S,23S,25S,26S,28S,30S,31S,33S,35S,36S,38S,40S,41R,43R,44R,45R,46R,47R,48R,49R,50R,51R,52R,53R,54R,55R,56R)-10,15,20,25,30,35,40-heptakis(2-carboxyethylsulfanylmethyl)-41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56-hexadecahydroxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34,37,39-hexadecaoxanonacyclo[36.2.2.23,6.28,11.213,16.218,21.223,26.228,31.233,36]hexapentacontan-5-yl]methylsulfanyl]propanoic acid

Also known as: Sugammadex, SUGAMMADEX

Parent form; salt/anhydrous children: CHEMBL2107374

Patent coverage: 17 distinct patent families (22 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
burn	3	MONDO:0043519	EFO:0009516
morbid obesity	2	MONDO:0005139	EFO:0001074
obesity disorder	2	MONDO:0011122	EFO:0001073
kidney disorder	2	MONDO:0005240	EFO:0003086
allergic disease	1	MONDO:0005271	MONDO:0005271

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 208.

Phase distribution

Phase	Trials
PHASE4	94
Not specified	54
PHASE3	34
PHASE2	14
PHASE1	6
PHASE2/PHASE3	3
PHASE1/PHASE2	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06112353	PHASE4	RECRUITING	Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
NCT07203287	PHASE4	RECRUITING	Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
NCT07477132	PHASE4	NOT_YET_RECRUITING	A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old
NCT00895609	PHASE4	COMPLETED	Sugammadex and Neostigmine at Shallow Neuromuscular Blockade
NCT01101139	PHASE4	COMPLETED	Sugammadex Improves Muscle Function After Standard Neuromuscular Recovery
NCT01142648	PHASE4	COMPLETED	Sugammadex and Brain Waves
NCT01424488	PHASE4	UNKNOWN	Sugammadex Efficacy and Safety for Reversal of Pipecuronium-induced Neuromuscular Blockade
NCT01453530	PHASE4	UNKNOWN	Street Fitness in Surgical Patients Undergoing General Anesthesia After Reversal of Neuromuscular Blockade
NCT01539044	PHASE4	COMPLETED	Optimal Relaxation Technique for Laparotomies With Rocuronium Infusion Followed by Sugammadex Reversal
NCT01579851	PHASE4	COMPLETED	Recovery After Sugammadex(Propofol vs Sevoflurane)
NCT01718236	PHASE4	COMPLETED	Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section
NCT01728584	PHASE4	COMPLETED	A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)
NCT01761552	PHASE4	UNKNOWN	A Prospective, Randomized Controlled Trial Comparing Traditional Methods of Neuromuscular Block Reversal to Sugammadex for Extubation in the Operating Room in ASA 4 and 4E Patients
NCT01785758	PHASE4	COMPLETED	Efficacy and Safety of Sugammadex in Renal Diseased Patients
NCT01933425	PHASE4	COMPLETED	Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade
NCT01965067	PHASE4	COMPLETED	Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex
NCT01972659	PHASE4	COMPLETED	Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients
NCT02079337	PHASE4	COMPLETED	Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery
NCT02160223	PHASE4	COMPLETED	Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea
NCT02215382	PHASE4	COMPLETED	Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade
NCT02243943	PHASE4	COMPLETED	Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile
NCT02247466	PHASE4	COMPLETED	Optimizing Surgical Conditions During Laparoscopic Herniotomy With Deep Neuromuscular Blockade
NCT02256280	PHASE4	TERMINATED	A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia
NCT02284412	PHASE4	COMPLETED	Functional Respiratory Imaging After Neostigmine or Sugammadex
NCT02286752	PHASE4	COMPLETED	Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting.
NCT02329964	PHASE4	UNKNOWN	Effectiveness of Sugammadex in LMS Surgery
NCT02361060	PHASE4	COMPLETED	Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery
NCT02375217	PHASE4	COMPLETED	Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy
NCT02390817	PHASE4	COMPLETED	Effect of Sugammadex for Muscle Motor Response and Awareness in Intraoperative Wakeup
NCT02403063	PHASE4	COMPLETED	Electromyographic Activity of the Respiratory Muscles During Neostigmine or Sugammadex Enhanced Recovery After Neuromuscular Blockade
NCT02410590	PHASE4	WITHDRAWN	Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)
NCT02414880	PHASE4	COMPLETED	Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection
NCT02451202	PHASE4	COMPLETED	Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures
NCT02455921	PHASE4	COMPLETED	Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children
NCT02484651	PHASE4	COMPLETED	Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?
NCT02568345	PHASE4	COMPLETED	Sugammadex ED90 Dose in the Obese Patients
NCT02580188	PHASE4	COMPLETED	The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery
NCT02698969	PHASE4	UNKNOWN	Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography
NCT02708056	PHASE4	COMPLETED	Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants
NCT02724111	PHASE4	COMPLETED	Effect of Neuromuscular Blockade on Operating Conditions and Overall Satisfaction During Spinal Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).